What is Breethe?
Breethe, Inc. is a pioneering medical device startup focused on revolutionizing the treatment of acute and chronic lung problems. The company is developing a compact artificial lung (ECMO) designed to significantly improve clinical practice and patient outcomes. Lung failure, a condition affecting over 235,000 individuals annually in the United States, currently has limited treatment options that often fail to provide the necessary lung support for healing and rehabilitation. Breethe aims to address this critical unmet need with its advanced technology, promising to enhance recovery and elevate the quality of life for patients.
How much funding has Breethe raised?
Breethe has raised a total of $4.1M across 2 funding rounds:
Private Equity
$1.1M
Private Equity
$3M
Private Equity (2017): $1.1M, investors not publicly disclosed
Private Equity (2017): $3M, investors not publicly disclosed
What's next for Breethe?
With this substantial enterprise-level backing, Breethe is poised to accelerate its development and commercialization efforts. The major strategic investment signals confidence from investors in the company's potential to disrupt the medical device market. This capital infusion will likely fuel further research and development, clinical trials, and the scaling of manufacturing capabilities. Breethe's focus on addressing a critical gap in lung failure treatment positions it for significant growth and impact in the healthcare sector.
See full Breethe company page
